Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-08-24 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin Limited has received FDA approval for a generic drug (Formoterol Fumarate Inhalation Solution). It is a corporate announcement about regulatory approval of a product, not a financial report, earnings release, or any other regulatory filing. The document is short (2404 characters) and does not contain financial data or detailed report content. It is not an announcement of a shareholder meeting, nor does it relate to management changes, capital updates, or legal proceedings. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2022-08-24 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 116 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or filing type. Given the lack of content, the document best fits the fallback category for miscellaneous filings that do not fit other categories, which is Regulatory Filings (RNS).
2022-08-24 English
Disclosure pursuant to Allotment of 30113 shares under ESOP.
Share Issue/Capital Change Classification · 95% confidence The document is a short disclosure letter addressed to a stock exchange (BSE Limited) regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It mentions the allotment of fully paid-up equity shares and the resulting increase in the company's issued and paid-up capital. The document references Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about share allotments and capital changes. The document length is only 1062 characters, indicating it is a brief announcement rather than a detailed report. There are no financial statements or detailed financial analysis present. Therefore, this document is best classified as a Share Issue/Capital Change announcement (SHA).
2022-08-24 English
Loss of share certificate
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015. It details lost share certificates and is addressed to the stock exchange. The content is a regulatory compliance communication rather than a financial report or announcement of voting results, management changes, or capital changes. It is a formal regulatory filing related to share certificate handling and transfer restrictions. The document length is short and it does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS).
2022-08-22 English
Intimation regarding Loss of Share Certificate by Shareholders.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) 2015. It provides details of lost share certificates and requests stop transfer of those shares. The content is a regulatory notification about share certificate loss and related administrative action. It does not contain financial data, management discussion, or any report. It is a regulatory filing informing the exchange about share certificate issues under a specific regulation. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is not an announcement of a report but a direct regulatory communication.
2022-08-22 English
Lupin Receives Approval from U.S. FDA for Rufinamide Tablets USP.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product (Rufinamide Tablets USP). It is addressed to stock exchanges and regulatory bodies as a disclosure pursuant to SEBI regulations. The content focuses on the announcement of regulatory approval and product launch information, not on financial results, management changes, or detailed financial data. The document length is 3402 characters, which is relatively short and typical for a press release or regulatory disclosure. There is no detailed financial report, earnings data, or management discussion. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report.
2022-08-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.